ArticleThe American journal of pathology2014
Mucosal pre-exposure to Th17-inducing adjuvants exacerbates pathology after influenza infection.
Article in The American journal of pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 42 citations in OpenAlex.
- B cells and iBALT in TB immunity & pathogenesis.Frontiers in immunology · 2026Review
- Seasonal PMParticle and fibre toxicology · 2025Article
- Saponin TQL1055 adjuvant-containing vaccine confers protection uponHuman vaccines & immunotherapeutics · 2024Article
- Review
- IL-17RA promotes pathologic epithelial inflammation in a mouse model of upper respiratory influenza infection.PLoS pathogens · 2023Article
- Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG.Pharmaceutics · 2023Article
- Bona Fide Th17 Cells without Th1 Functional Plasticity Protect against Influenza.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Clonotypic analysis of protective influenza M2e-specific lung resident Th17 memory cells reveals extensive functional diversity.Mucosal immunology · 2022Article
- Correlation between interleukin gene polymorphisms and current prevalence and mortality rates due to novel coronavirus disease 2019 (COVID-2019) in 23 countries.Journal of medical virology · 2021Article
- Is the oral microbiome a source to enhance mucosal immunity against infectious diseases?NPJ vaccines · 2021Review
- A Novel Bifunctional Fusion Protein, Vunakizumab-IL22, for Protection Against Pulmonary Immune Injury Caused by Influenza Virus.Frontiers in immunology · 2021Article
- Inter- Versus Intra-Host Sequence Diversity of pH1N1 and Associated Clinical Outcomes.Microorganisms · 2020Article
- Targeting the IL-22/IL-22BP axis enhances tight junctions and reduces inflammation during influenza infection.Mucosal immunology · 2020Article
- Highly Pathogenic Avian Influenza H5 Hemagglutinin Fused with the A Subunit of Type IIbVaccines · 2019Article
- Double-Edged Role of Interleukin 17A in Streptococcus pneumoniae Pathogenesis During Influenza Virus Coinfection.The Journal of infectious diseases · 2019Article
- Review
- Friend or Foe: The Protective and Pathological Roles of Inducible Bronchus-Associated Lymphoid Tissue in Pulmonary Diseases.Journal of immunology (Baltimore, Md. : 1950) · 2019Review
- M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection.Mucosal immunology · 2018Article
- Role of Inflammatory Risk Factors in the Pathogenesis ofFrontiers in immunology · 2018Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
Abstract
Mucosal vaccines are thought to confer superior protection against mucosal infectious diseases. In addition, mucosal routes of vaccine delivery preferentially induce the generation of T helper 17 (Th17) cells, which produce the cytokine IL-17. Th17 cells are critical in mediating vaccine-induced immunity against several mucosal infectious diseases. However, IL-17 is also a potent proinflammatory cytokine, and we recently showed that IL-17 mediates immunopathology and lung injury after influenza infection in mice. In the present study, we tested the hypothesis that mucosal pre-exposure to Th17-inducing adjuvants can promote disease exacerbation upon subsequent infection with influenza virus. Mice mucosally pre-exposed to Th17-inducing adjuvants, such as type II heat-labile enterotoxin or cholera toxin, resulted in increased morbidity and exacerbated lung inflammation upon subsequent infection with influenza virus. Furthermore, the increased morbidity was accompanied by increased expression of inflammatory chemokines and increased accumulation of neutrophils. Importantly, blockade of the IL-17 pathway in mice pre-exposed to Th17-inducing adjuvants resulted in attenuation of the inflammatory phenotype seen in influenza-infected mice. Our findings indicate that, before mucosal Th17-inducing adjuvants can be used in vaccine strategies, the short- and long-term detrimental effects of such adjuvants on disease exacerbation and lung injury in response to infections, such as influenza, should be carefully studied.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.